Canada's Valeant again ups bid for Botox maker

Canadian pharmaceutical firm Valeant on Friday upped for the second time in a week its hostile bid for Allergan, the US maker of Botox, to $53.5 billion.

The new offer translates to $72 per share in cash, plus 0.83 of its shares for each Allergan share.

That puts the total value for the bid at about $179 per share in cash and stock, based on Valeant's latest share price.

The company two days earlier had made an offer worth about $50 billion.

Valeant also announced that Pershing Square, Allergan's largest shareholder with a 9.7 percent stake, has agreed to sell its holdings, but will only take shares and not cash.

"We believe that our gesture to the other Allergan owners makes an extraordinarily strong statement about our belief in the long-term value of this highly strategic business combination," Pershing Square chief executive Bill Ackman said in a statement.

Allergan has rebuffed Valeant's courtship since it was first announced in April, criticizing its business model and even hiring a consultant analyst to pick apart its alleged shortfalls in a report, which Valeant said contained "numerous errors and mis-statements of facts."

add to favorites email to friend print save as pdf

Related Stories

Valeant raises cash-stock offer for Allergan (Update)

May 28, 2014

Valeant Pharmaceuticals has pumped more cash into its bid for Botox maker Allergan, and it also defended its business model on Wednesday, a day after its reluctant acquisition target aired more concerns about ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

Recommended for you

Were clinical trial practices in East Germany questionable?

Oct 23, 2014

Clinical trials carried out in the former East Germany in the second half of the 20th century were not always with the full knowledge or understanding of participants with some questionable practices taking place, according ...

Schumacher's doctor sees progress after injury

Oct 23, 2014

A French physician who treated Michael Schumacher for nearly six months after the Formula One champion struck his head in a ski accident says he is no longer in a coma and predicted a possible recovery within three years.

User comments